Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts. - Suzuki R; Watanabe S; Shono K; Masuda T; Yanai K; Yamazaki R; Ando Y; Wakabayashi T; Tanaka S; Sekiya T; Kushiro K; Yanagimura N; et al. (Cancer immunology, immunotherapy : CII, 2026)